Press releases about CCARL

InSilico Medicine announces collaboration with Canada Cancer and Aging Research Laboratories

PUBLIC RELEASE DATE: 23-Oct-2014

Insilico Medicine to fund CCARL’s pilot research study in personalized medicine and aging research. InSilico Medicine, the company focused on drug discovery for cancer and age-related diseases, announced its investment in a research collaboration with Canada Cancer and Aging Research Laboratories, Inc (CCARL). The companies will collaborate on improving decision making in clinical oncology and discovery, and personalized medicine projects in multiple sclerosis (MS). See the full story:

http://www.eurekalert.org/pub_releases/2014-10/imi-ima102314.php

Canada Cancer and Aging Research Laboratory (CCARL) Launched in Lethbridge to Provide Personalized Diagnostic and Medical Solutions for Cancer and Age-Related Diseases

Lethbridge, AB, Canada (PRWEB) October 07, 2014 

Canada Cancer and Aging Research Laboratory (CCARL) today announced the launch of its personalized medicine and research programs in Canada. The company plans to unfold its operations in two phases, working in the areas of a personalized medical approach for cancer treatment and combating aging and age-related diseases. See full story:

http://www.prweb.com/releases/2014/10/prweb12232415.htm

Canada Cancer and Aging Research Laboratory was launched with plans to unfold its operations in two phases. In the first phase it will develop a partnership with Pathway Pharmaceuticals in Hong Kong to offer the OncoFinder technology in Canada.  See full story:
http://www.genomeweb.com/brief-week-jackson-lab-techcomp-bruker-sistemic-tc-biopharm-canada-cancer-and-ag